{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000082","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.114078+00:00","generated_at":"2026-05-17T02:19:02.027952+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xencor reports 25% ORR for XmAb819 in ccRCC Phase 1; dose-expansion cohort selected","bullets":["XmAb819 (ENPP3 x CD3) Phase 1: 25% ORR (5/20 PRs) and 70% DCR in target dose range in heavily pre-treated ccRCC.","All 5 responders remain on treatment; 50% (10/20) of evaluable patients in target range remain on treatment as of Sep 19, 2025.","Safety: CRS (Grade 3 in 4% with correct priming dose), no ICANS, no Grade 5 events; priming dose errors identified and remediated.","First dose-expansion cohort enrolled; expect Phase 3 dose selection in 2026, pivotal study start in 2027.","Early XmAb541 (CLDN6 x CD3) data also presented in ovarian, endometrial, and germ cell tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000082","json":"https://secwatch.observer/filing/0001326732-25-000082.json","markdown":"https://secwatch.observer/filing/0001326732-25-000082.md","text":"https://secwatch.observer/filing/0001326732-25-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000082/0001326732-25-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000082/xncr-20251024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:19:02.027952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}